Perspective Therapeutics Files 8-K/A Amendment
Ticker: CATX · Form: 8-K/A · Filed: Aug 12, 2024 · CIK: 728387
Sentiment: neutral
Topics: amendment, financial-reporting
TL;DR
Perspective Therapeutics filed an 8-K/A amendment on Aug 12, 2024, updating financial/operational info.
AI Summary
Perspective Therapeutics, Inc. filed an 8-K/A on August 12, 2024, to amend a previous filing. The amendment pertains to the company's results of operations and financial condition, as well as financial statements and exhibits. The filing does not provide specific new financial figures or operational updates in this amendment.
Why It Matters
This filing indicates an update or correction to previously disclosed financial information or operational details, which could be important for investors assessing the company's current status.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing and does not introduce new material events or financial information that would inherently increase risk.
Key Players & Entities
- Perspective Therapeutics, Inc. (company) — Registrant
- August 12, 2024 (date) — Date of Report
- Isoray, Inc. (company) — Former Company Name
- IsoRay, Inc. (company) — Former Company Name
- CENTURY PARK PICTURES CORP (company) — Former Company Name
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing serves to amend a previous report concerning the company's results of operations and financial condition, and financial statements and exhibits.
When was this amendment filed?
The amendment was filed on August 12, 2024.
What specific financial information is being amended?
The filing indicates an amendment related to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail the specific changes within this document.
What was the company formerly known as?
The company was formerly known as Isoray, Inc., IsoRay, Inc., and CENTURY PARK PICTURES CORP.
Where is Perspective Therapeutics, Inc. located?
The company's business and mail address is 2401 Elliott Avenue, Suite 320, Seattle, Washington 98121.
Filing Stats: 625 words · 3 min read · ~2 pages · Grade level 11.4 · Accepted 2024-08-12 17:22:36
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CATX NYSE American LLC
Filing Documents
- catx-20240812.htm (8-K/A) — 39KB
- catx-ex99_1.htm (EX-99.1) — 214KB
- img236230851_0.jpg (GRAPHIC) — 73KB
- 0000950170-24-095547.txt ( ) — 486KB
- catx-20240812.xsd (EX-101.SCH) — 24KB
- catx-20240812_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 12, 2024, Perspective Therapeutics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended June 30, 2024 and providing recent business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company's filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. 99.1 Press release issued by Perspective Therapeutics, Inc., dated August 12, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PERSPECTIVE THERAPEUTICS, INC. Date: August 12, 2024 By: /s/ Johan (Thijs) Spoor Johan (Thijs) Spoor Chief Executive Officer